ENTERO THERAPEUTICS INC (ENTO) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:ENTO • US33749P5070

2.99 USD
+0.15 (+5.28%)
At close: Nov 28, 2025
3.2 USD
+0.21 (+7.02%)
After Hours: 11/28/2025, 8:25:57 PM
Fundamental Rating

1

Taking everything into account, ENTO scores 1 out of 10 in our fundamental rating. ENTO was compared to 524 industry peers in the Biotechnology industry. Both the profitability and financial health of ENTO have multiple concerns. ENTO does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • In the past year ENTO has reported negative net income.
  • In the past year ENTO has reported a negative cash flow from operations.
  • ENTO had negative earnings in each of the past 5 years.
  • In the past 5 years ENTO always reported negative operating cash flow.
ENTO Yearly Net Income VS EBIT VS OCF VS FCFENTO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -20.48%, ENTO is in the better half of the industry, outperforming 75.33% of the companies in the same industry.
  • ENTO has a better Return On Equity (-31.45%) than 75.33% of its industry peers.
Industry RankSector Rank
ROA -20.48%
ROE -31.45%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ENTO Yearly ROA, ROE, ROICENTO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 -10K -20K -30K

1.3 Margins

  • ENTO does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ENTO Yearly Profit, Operating, Gross MarginsENTO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2023 2024

More info and screens

3

2. Health

2.1 Basic Checks

  • Compared to 1 year ago, ENTO has more shares outstanding
  • ENTO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ENTO Yearly Shares OutstandingENTO Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 500K 1M 1.5M
ENTO Yearly Total Debt VS Total AssetsENTO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

  • Based on the Altman-Z score of -2.59, we must say that ENTO is in the distress zone and has some risk of bankruptcy.
  • ENTO has a Altman-Z score (-2.59) which is in line with its industry peers.
  • ENTO has a Debt/Equity ratio of 0.01. This is a healthy value indicating a solid balance between debt and equity.
  • The Debt to Equity ratio of ENTO (0.01) is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Altman-Z -2.59
ROIC/WACCN/A
WACCN/A
ENTO Yearly LT Debt VS Equity VS FCFENTO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 0 20M -20M 40M

2.3 Liquidity

  • A Current Ratio of 2.81 indicates that ENTO has no problem at all paying its short term obligations.
  • Looking at the Current ratio, with a value of 2.81, ENTO is doing worse than 67.66% of the companies in the same industry.
  • A Quick Ratio of 2.81 indicates that ENTO has no problem at all paying its short term obligations.
  • ENTO has a Quick ratio of 2.81. This is in the lower half of the industry: ENTO underperforms 65.79% of its industry peers.
Industry RankSector Rank
Current Ratio 2.81
Quick Ratio 2.81
ENTO Yearly Current Assets VS Current LiabilitesENTO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 20M 40M 60M 80M

More info and screens

1

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 76.71% over the past year.
EPS 1Y (TTM)76.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%94.12%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • ENTO is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 31.66% yearly.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-34.51%
EPS Next 2Y-24.09%
EPS Next 3Y-13.45%
EPS Next 5Y31.66%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ENTO Yearly Revenue VS EstimatesENTO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2028 2029 2030 100M 200M 300M
ENTO Yearly EPS VS EstimatesENTO Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -100K -200K -300K

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for ENTO. In the last year negative earnings were reported.
  • Also next year ENTO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ENTO Price Earnings VS Forward Price EarningsENTO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ENTO Per share dataENTO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10 -10 15

4.3 Compensation for Growth

  • A cheap valuation may be justified as ENTO's earnings are expected to decrease with -13.45% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-24.09%
EPS Next 3Y-13.45%

More info and screens

0

5. Dividend

5.1 Amount

  • ENTO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ENTERO THERAPEUTICS INC / ENTO FAQ

What is the fundamental rating for ENTO stock?

ChartMill assigns a fundamental rating of 1 / 10 to ENTO.


What is the valuation status of ENTERO THERAPEUTICS INC (ENTO) stock?

ChartMill assigns a valuation rating of 0 / 10 to ENTERO THERAPEUTICS INC (ENTO). This can be considered as Overvalued.


What is the profitability of ENTO stock?

ENTERO THERAPEUTICS INC (ENTO) has a profitability rating of 1 / 10.


What is the financial health of ENTERO THERAPEUTICS INC (ENTO) stock?

The financial health rating of ENTERO THERAPEUTICS INC (ENTO) is 3 / 10.


Can you provide the expected EPS growth for ENTO stock?

The Earnings per Share (EPS) of ENTERO THERAPEUTICS INC (ENTO) is expected to decline by -34.51% in the next year.